2025
JANUARY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 1
309
THE EFFECT OF VITAMIN D ON THE MUSCULOSKELETAL SYSTEM OF WOMEN
DURING MENOPAUSE
Ochilova Nusratoy Ismoil qizi
2nd year master's resident of SamDTU
Indiaminova G.N.
Scientific supervisor: PhD.
https://doi.org/10.5281/zenodo.14677199
Objective
: Almost every cell in the div has a specific binding site for vitamin D on its
surface - the VDR receptor (vitamin D receptor). Such receptors are present in almost all organs
and tissues, with the highest concentrations observed in cells of the central nervous system, adipose
tissue, cells of the immune system, muscles, tissues of the pancreas and the reproductive system.
Materials and methods of research.
As a result of hypovitaminosis in childhood, the
formation of the bone tissue peak is disrupted, which affects the strength of bone tissue throughout
life. The problem of vitamin D deficiency is relevant for both children and adults (especially in
old age). Thus, D-hypovitaminosis is observed in 73.7% of women and 61.7% of men. Severe,
long-term vitamin D deficiency leads to hypocalcemia and secondary hyperparathyroidism, which
leads to phosphate loss in the urine, bone demineralization, and ultimately osteomalacia (a
condition in which the bones become thin, deformed, and easily broken).
Vitamin D deficiency is especially dangerous for women during menopause, as the level
of sex hormones decreases at this time, which leads to bone loss. Hypovitaminosis accelerates this
process and, as a result, osteoporosis develops (a disease associated with the loss of calcium in the
bones, which makes the bones more fragile and easily damaged). This condition is accompanied
by joint pain, large bones and frequent fractures, which can be critical in old age and are not fully
reversible.
As mentioned above, vitamin D has regulatory activity on a large number of genes,
including those affecting cell cycle, immunity, and metabolism. Recently, new information has
emerged about the association between an increased risk of developing cancer and reduced blood
levels of vitamin D.
Any other proliferation without differentiation, such as uncontrolled cell division and
mutations, can lead to oncology. Vitamin D inhibits proliferation and stimulates cell
differentiation, preventing the growth of cancer cells, which makes it effective in the prevention
and treatment of breast, ovarian, prostate, rectal, stomach, bladder, esophagus, kidney, lung,
pancreas, brain cancer, leukemia, myeloma, lymphoma.
2025
JANUARY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 1
310
Research results.
All possible dosage options for vitamin D are presented in the D3-CAPS
line, manufactured by the Minskintercaps unitary enterprise. The entire line (D3-CAPS ULTRA
500 IU, D3-CAPS 2000 IU and D3-CAPS 5000 IU, IU, D3-CAPS MAXIMA 50000 IU) is
designed for the treatment and prevention of vitamin D hypovitaminosis in adults and children.
taking into account international national recommendations with the participation of leading health
experts. For the treatment of vitamin D deficiency, it is recommended to use preparations
containing a higher content of cholecalciferol, for example, D3-CAPS, available in two dosages:
2000 IU and 5000 IU. Use of D3-CAPS 2000 ME Treatment of vitamin D deficiency in adults and
adolescents over 12 years of age: 1 capsule per day for moderate D deficiency (25 (OH) D - 10-
20 ng / ml) for a high course. To decide on the transition to prophylactic doses, laboratory
monitoring of 25 (OH) D in the blood for 6-8 weeks. For the prevention and complex treatment of
osteoporosis for people over 60 years of age: D3-CAPS 2000 ME , 1 capsule per day. D3-CAPS
2000 IU - a daily dose in one capsule for the prevention of low-traumatic fractures in the elderly
in the complex treatment of osteoporosis. If the amount of calcium from food is insufficient,
calcium preparations should be used to meet the daily need for this element. Use of D3-CAPS
5000 IU Treatment of vitamin D deficiency in adults and adolescents aged 12-18 years: take 1
capsule of D3-CAPS 5000 IU per day, then every 3 months with laboratory monitoring of 25 (OH)
D in the blood to decide on the transition to prophylactic doses or continuation of treatment. D3-
CAPS 5000 IU - a daily dose of vitamin D in one capsule for patients at high risk of vitamin D
deficiency (malabsorption in the gastrointestinal tract, obesity, chronic liver and kidney diseases).
It should be taken into account that for diseases/conditions accompanied by impaired absorption
of vitamin D, daily intake of vitamin D is preferable to optimize absorption. The recommended
dose of cholecalciferol for the treatment of vitamin D deficiency should be 2-3 times higher than
the daily requirement of the age group (minimum 6000-10000 IU / day). D3-CAPS MAXIMA
50,000 IU Treatment of vitamin D deficiency in adults (from 18 years of age): - Treatment of
severe vitamin D deficiency (level 25 (OH) D < 10 ng/ml) – 1 capsule per week (laboratory control
of serum 25 (OH) D once every 3 months).
Conclusion:
Vitamin D is a potent immunomodulator that strengthens innate immunity
and prevents the development of autoimmune diseases. There is a direct link between low vitamin
D levels and frequent acute respiratory infections. Vitamin D protects against respiratory
infections by increasing the level of antimicrobial peptides in the lungs. The immunomodulatory
activity of vitamin D is confirmed by data from large clinical trials showing the high efficacy and
safety of topical vitamin D drugs in the treatment of psoriasis. Also in this literature there is a link
2025
JANUARY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 1
311
between low vitamin D levels and atopic dermatitis, severe bronchial asthma, rheumatoid arthritis,
autoimmune thyroid diseases and multiple sclerosis.
REFERENCES
1.
Kedrinskaya A. G., Obraztsova G. I., Nagornaya I. I. Cardiovascular lesions in children
with obesity //POPULATION. – 2015. – Т. 69. – №. 74. – С. 980.
2.
Ашурова М. Ж., Гарифулина Л. М. Минеральная плотность костей и уровень
Витамина Д У ДЕТЕЙ с ожирением //Children's Medicine of the North-West. – 2020. –
Т. 8. – №. 1. – С. 44-44.
3.
Гарифулина Л. М., Ашурова М. Д., Тураева Д. Х. Характер питания и качество жизни
детей с экзогенно-конституциональным ожирением //Достижения науки и
образования. – 2019. – №. 10 (51). – С. 46-49.
4.
Гарифулина Л. М., Ашурова М. Ж., Гойибова Н. С. Состояние здоровья детей с
различными типами ожирения //Молодежь и медицинская наука в XXI веке. – 2018.
– С. 35-37.
5.
Гарифулина Л. М., Ашурова М. Д., Гойибова Н. С. Совершенствование терапии
метаболического синдрома у подростков при помощи применения α-липоевой
кислоты //Наука, техника и образование. – 2018. – №. 10 (51). – С. 69-72.
6.
Ашурова М. БОЛАЛАР ВА ЎСМИРЛАРДА СЕМИЗЛИК ВА Д ВИТАМИНИ
ДЕФИЦИТИ //Журнал гепато-гастроэнтерологических исследований. – 2020. – Т. 1.
– №. 3. – С. 66-71.
7.
Сорокман Т. В., Попелюк М. А. В., Ушакова Е. Ю. Прогностические критерии
развития метаболического синдрома у детей //Здоровье ребенка. – 2016. – №. 2 (70).
– С. 29-32.
8.
Жамшедовна А. M., Гарифулина Л. М. Болалар ва ўсмирларда семизлик ва д
витамини дефицити, муаммога замонавий қарашлар //Журнал гепато-
гастроэнтерологических исследований. – 2022. – Т. 3. – №. 2.
9.
Жамшедовна А. M., СЕМИЗЛИК Г. ВА Д ВИТАМИНИ ДЕФИЦИТИ, МУАММОГА
ЗАМОНАВИЙ
ҚАРАШЛАР
//ЖУРНАЛ
ГЕПАТО-
ГАСТРОЭНТЕРОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ. – 2022. – Т. 3. – №. 2.
10.
Ишкабулова Г. Д. и др. Влияние димефосфона на основные функции почек
новорожденных, рожденных от матерей с хроническим пиелонефритом с
2025
JANUARY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 1
312
сочетанным ОПГ-гестозом //Вестник науки и образования. – 2018. – №. 14-2 (50). –
С. 51-55.
11.
Ашурова М. Ж., Гарифулина Л. М. Болалар ва ўсмирларда семизлик ва Д витамини
дефицити, муаммога замонавий қарашлар //YfcS^ VXbSea § VSdecapeXca^ aV
[jXd][h [dd^ XWaUS[\. – 2020. – С. 8.
12.
Кудратова Г. Н. и др. Болаларда ўткир панкератитни учраши ва клиник кечиши
//Научно-практический журнал “Доктор ахборотномаси. – 2021. – Т. 3. – С. 100.
13.
Жамшедовна А. M., Гарифулина Л. М. Samarqand viloyatidagi semizligi bor bolаlаrdа
vitаmin d statusini baholash //Журнал гепато-гастроэнтерологических исследований.
– 2023. – Т. 4. – №. 2.
14.
Jamshedovna A. M., Maratovna G. L. Vitamin d level and bone mineral density status in
obese and overweight children //Вестник науки и образования. – 2020. – №. 10-4 (88).
– С. 98-100.
15.
Гарифулина Л., Ашурова М., Холмурадова З. Изменения сердечно-сосудистой
системы у подростков при ожирении и Артериальной гипертензии //Журнал
проблемы биологии и медицины. – 2018. – №. 1 (99). – С. 33-35.
16.
Holmuradovna T. D., Maratovna G. L., Jamshedovna A. M. OBESITY AS A RISK
FACTOR FOR HEPATOBILIARY SYSTEM DAMAGE IN CHILDREN //Galaxy
International Interdisciplinary Research Journal. – 2022. – Т. 10. – №. 6. – С. 454-462.
17.
Zhamshedovna A. M., Maratovna G. L. VITAMIN D LEVEL AND CONDITION OF
MINERAL BONE DENSITY IN CHILDREN WITH OBESITY AND OVERWEIGHT
//European Journal of Interdisciplinary Research and Development. – 2022. – Т. 4. – С.
84-86.
18.
Ашурова М. УРОВЕНЬ ВИТАМИНА Д И СОСТОЯНИЕ МИНЕРАЛЬНОЙ
ПЛОТНОСТИ КОСТЕЙ У ДЕТЕЙ С ОЖИРЕНИЕМ //Евразийский журнал
академических исследований. – 2024. – Т. 4. – №. 5. – С. 167-170.
19.
Исламова Д. С., Ашурова М. Ж. Особенности Желчевыделительной Системы У
Детей Старшего Возраста И Её Влияние На Их Здоровье //Miasto Przyszłości. – 2024.
– Т. 52. – С. 212-214.
20.
Юсупова М. М. и др. Факторы риска у полиморбидных детей //Тюменский
медицинский журнал. – 2011. – №. 2. – С. 31-32.
2025
JANUARY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 1
313
21.
Гарифулина Л., Ашурова М. Комплексная клинико-метаболическая оценка
состояния детей с ожирением и артериальной гипертензией //Журнал проблемы
биологии и медицины. – 2017. – №. 2 (94). – С. 31-34.
22.
Ашурова М. ОЖИРЕНИЕ И ДЕФИЦИТ ВИТАМИНА Д У ДЕТЕЙ И ПОДРОСТКОВ
//Журнал гепато-гастроэнтерологических исследований. – 2020. – Т. 1. – №. 3. – С.
66-71.
23.
Maratovna G. L., Zhamshedovna A. M., Salimovna G. N. Characteristic of the
cardiovascular system in children and adolescents at obesity in accompanience of arterial
hypertension //CUTTING EDGE-SCIENCE. – 2020. – С. 33.
24.
Жамшедовна А. M., Гарифулина Л. М. SEMIZLIGI BOR BOLАLАRDА VITАMIN D
DEFITSITI
HOLАTLАRINI
АNIQLАSH
//ЖУРНАЛ
ГЕПАТО-
ГАСТРОЭНТЕРОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ. – 2022. – Т. 3. – №. 1.
25.
Maratovna G. L., Salimovna G. N., Zhamshedovna A. M. FEATURES OF KIDNEY
DAMAGE IN CHILDREN WITH OBESITY //Galaxy International Interdisciplinary
Research Journal. – 2022. – Т. 10. – №. 6. – С. 445-453.
26.
Jamshedovna А. M., Maratovna G. L. SEMIZLIGI BOR BOLАLАRDА VITАMIN “D”
DEFITSITI HOLАTLАRINI АNIQLАSH //T [a_XW [i [S US S_S^[ǜe YfcS^. – С. 99.
27.
Ашурова М. Ж., Абдусалямов А. А. Лекарственная безопасность с позиций педиатра
стационара //Тюменский медицинский журнал. – 2011. – №. 2. – С. 21.
28.
Гарифулина Л., Ашурова М., Атаева М. Некоторые метаболические показатели у
детей с ожирением и артериальной гипертензией //Журнал вестник врача. – 2012. –
Т. 1. – №. 2. – С. 54-55.
29.
Рустамов M. и др. Антибиотикотерапия в педиатрии с точки зрения концепции
изолированных пространств //Журнал вестник врача. – 2012. – Т. 1. – №. 3. – С. 134-
144.
30.
Гарифулина Л., Ашурова М. Комплексная клинико-метаболическая оценка
состояния детей с ожирением и артериальной гипертензией //Журнал проблемы
биологии и медицины. – 2017. – №. 2 (94). – С. 31-34.
